Trials / Completed
CompletedNCT00818155
Study Evaluating the Safety, Tolerability and Pharmacokinetics of Desvenlafaxine Succinate SR in Healthy Chinese Male and Females
Ascending Single Dose Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Desvenlafaxine Succinate Sustained Release Administered Orally to Healthy Chinese Subjects.
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 36 (actual)
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer · Industry
- Sex
- All
- Age
- 18 Years – 45 Years
- Healthy volunteers
- Accepted
Summary
The main purpose of this study is to evaluate the safety and tolerability of desvenlafaxine succinate SR in healthy male and female Chinese subjects. The amount of drug in the body and the effects of the drug will also be evaluated.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | desvenlafaxine succinate SR | desvenlafaxine succinate SR |
| OTHER | Placebo |
Timeline
- Start date
- 2009-01-01
- Primary completion
- 2009-02-01
- Completion
- 2009-02-01
- First posted
- 2009-01-07
- Last updated
- 2013-01-29
Source: ClinicalTrials.gov record NCT00818155. Inclusion in this directory is not an endorsement.